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Objectives: To determine whether renal perfusion
with cold crystalloid solution enriched with histidine-tryp-
tophan-ketoglutarate (Custodiol) provides better protec-
tion against renal ischemic injury than cold lactated
Ringer’s solution in patients undergoing suprarenal aortic
aneurysm (sAAA) open repair.
Methods: We reviewed 256 consecutive patients un-
dergoing sAAA open repair between 1993 and 2013. In
181 cases, direct perfusion of at least one renal artery was
performed. Among these patients, 87 had cold renal perfu-
sion with Ringer’s lactate solution and 94 with Custodiol so-
lution. Propensity score matching based on baseline clinical
variables that were expected to inﬂuence renal outcomes was
performed to correct for any bias that may have been asso-
ciated with the use of Custodiol. Postoperative acute renal
dysfunction (ARD) stratiﬁed in ﬁve classes according to
postoperative serum creatinine elevation and need for dial-
ysis was compared in the two groups, and independent pre-
dictors of ARD were identiﬁed at multivariate analysis.
Results: After propensity score matching we were able
to match 74 Custodiol cases one-to-one to those receiving
perfusion with lactated Ringer’s solution. Overall 30-day
mortality was 3.4%, temporary hemodialysis or continuous
venovenous hemoﬁltration was 4.7%, and dialysis at
discharge was 2.7%. Freedom from ARD >2 (>100%
elevation in baseline ceratinine level) and from the need
for dialysis were signiﬁcantly increased in the Custodiol
group (P ¼ .007 and P ¼ .04, respectively). At multivariate
analysis, Custodiol perfusion and clamping time were the
independent predictors of non-ARD >2.
Conclusions: In this series of sAAA repair, perfusion
with (4C) Custodiol offered superior renal protection
when compared with (4C) Ringer’s lactate. Larger series
and/or randomized trials are needed to conﬁrm this ﬁnding.
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Objectives: To evaluate the level of endoleak and the
decrease in size of infrarenal abdominal aortic aneurysm
(AAA) after coil embolization during endovascular aneu-
rysm repair (EVAR) for patients at risk for type II
endoleak.
Methods: Between 2009 and 2013, 80 patients with
AAA and a high risk for type II endoleak were treated
with coil embolization of the aneurysm sac during EVAR.
Embolization was performed using a microcatheter placed
between the stentgraft and the aortic aneurysm wall.
Follow-up using computed tomography (CT) scans (ﬁrst
month, 6 months, 1 year, and 1 years) was obtained to eval-
uate presence of endoleaks and the size of the aneurysm sac.
Results: The mean number of coils used for emboliza-
tion was 11 (range, 8-14 coils). Technical success was achieved
in all patients. Only one of 80 patients (1.2%) presented a type
II endoleak on follow-up CT scans. Statistical analysis (paired
t-test) showed a signiﬁcant decrease of the aneurysm diameter
at 6 months (P ¼ .036), 1 year (P ¼ .004), and 2 years (P ¼
.001). The mean follow-up period after treatment was 13
months (range, 1-29 months). There were no procedure-
related complications and two secondary interventions.
Conclusions: Coil embolization of the aneurysm
sac during EVAR for patients at risk for type II endo-
leak is technically feasible and clinically effective in pre-
venting type II endoleak. This led to a rapid decrease in
size of AAA and low level of secondary intervention.
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